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Background: Medullary thyroid carcinomas (MTC) account for 3% to 5% of all thyroid cancers.
In most cases, MTC is hereditary and occurs as part of the multiple endocrine neoplasia (MEN)
type 2A and 2B syndromes. There is a strong genotype-phenotype correlation associatedwith the
respective RETmutations, making risk-adaptedmanagement possible.
Procedure: We report the prospectively collected data on children and adolescents of the mul-
ticenter nonrandomized German GPOH-MET registry. Children and adolescents with MTC and
C-cell hyperplasia (CCH) were included.
Results:From1997 to June2019, a total of 57patientswithMTCand17withCCHwere reported.
In patients with MTC, median follow-up was five years (range, 0-19) and median age at diag-
nosis 10 years (range, 0-17). Overall survival and event-free survival (EFS) were 87% and 52%,
respectively. In total 96.4% of patients were affected by MEN2 syndromes, which was in 37/42
MEN2A and 3/28 MEN2B (M918T mutation) inherited. EFS in MEN2A was 78%, and in MEN2B
38% (P < 0.001). In multivariate analyses, lymph node (LN) status and postoperatively elevated
calcitoninwere significant prognostic factors for EFS. Notably, modest-riskmutation carriers pre-
sented withMTC at a rather young age, without raised calcitonin, and LNmetastases.
Conclusions: Identification of children carrying de novo RET M918T mutations by means of the
characteristic phenotype is crucial to detect MTC at an early stage, which will be associated with
improved survival. As calcitonin levels may be false-negative and modest-risk mutation carriers
present with a variable phenotype, particular attention should be paid to these children.
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1 INTRODUCTION
Medullary thyroid carcinoma (MTC) accounts for 3% to 5% of all
thyroid cancers in children and adults with an incidence in chil-
dren of 0.03 per 100.000 population per year.1,2 In most cases,
Abbreviations: (M)MTC, (metastatic) medullary thyroid carcinoma; ATA, American Thyroid Association; CCH, C-cell hyperplasia; CI, confidence interval; CPS, cancer predisposition syndrome; CR,
complete remission; EFS, event-free survival; H, high risk; HST, highest risk; MEN, multiple endocrine neoplasia; MET, malignant endocrine tumor;MOD,modest risk; OS, overall survival; PET,
positron emission tomography; PHEO, pheochromocytoma; PHPT, primary hyperparathyroidism; RLN, recurrent laryngeal nerve; SD, standard deviation; TE, thyroidectomy.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
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MTC is hereditary.2 Hereditary MTC occurs as part of the multiple
endocrine neoplasia (MEN) type 2A and 2B syndrome.3 MEN type 2
can additionally presentwith pheochromocytoma (PHEO) and primary
hyperparathyroidism (PHPT) (referred to as MEN2A) as well as
mucosal neurinomas, intestinal ganglioneuromatosis, and among
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others a marfanoid habitus (referred to as MEN2B).3–7 Almost all
MTCs diagnosed in childhood result from autosomal dominant inher-
ited or de novo gain-of-function pathogenic germline variants in the
RET proto-oncogene.3,8,9
In contrast to most cancer predisposition syndromes (CPS) in chil-
dren, there is a striking genotype-phenotype correlation and, thus, pre-
dictability for the development of the three pathognomonic tumors in
MEN2.4,10–13 Typically,MEN2 initiallymanifestswith thedevelopment
of MTC. However, the age of onset of MTC varies by genotype, from
early childhood (i.e., p.M918T, MEN2B) to adolescent and early adult-
hood and even middle age in MEN2A.6,10,12,13 The development of
MTC is preceded by calcitonin-secreting parafollicular C-cell hyperpla-
sia (CCH) and theprogression toMTC is age related.14 The latter corre-
lateswith the transforming capacity of the respectiveRETmutations.15
Guidelines for the management of patients with hereditary
MTC/MEN2 have been published by the American Thyroid Associ-
ation (ATA) in 2001 and have since then been modified thrice. The
pathogenic codon-specific variants are classified in “highest” (HST),
“high” (H), and “modest” (MOD) due to the clinical aggressiveness of
the MTC and to the incidence of PHEO and PHPT.10 Management of
mutation carriers including the recommended timing of prophylactic
thyroidectomy (TE) depends on the specific RET mutation. This takes
into account the probability of developing MTC at an early age and of
metastatic disease. Prophylactic TE is recommended in the first year
of life in carriers with highest risk mutation, at or before five years of
age based on serum calcitonin levels in the high-risk category, and in
modest-risk mutation carriers TE is recommended when the serum
calcitonin levels start to rise.10
Hence, pathogenicRETmutations afford the unique opportunity for
early treatment beforemetastatic and thus incurable disease has been
occurred. MEN2 syndromes represent an impressive paradigm of CPS
manifesting in childhood, inwhich individualizationof care andprophy-
lactic therapy based on the patient’smutation is possible. As illustrated
by the need for a repeated update ofATAguidelineswithin a short time
period, ongoing collection of data and outcomes is necessary to pro-
vide the most accurate, variant-specific risk estimates particularly in
carriers of moderate-risk alleles.
The clinical reality of the clinical situation inMEN2B syndrome con-
trasts with current recommendations. TheM918Tmutation of RET for
instance, conferring the highestMTC risk level, most frequently occurs
de novo.16,17 Thus, in case the characteristic phenotype is overlooked,
patients are diagnosedwithMEN2BwhenMTC is already present.
We herein report the data on all children and adolescents with
MTC and CCH reported to the German GPOH-MET study center
since 1997. We review the genotype-phenotype correlation of these
patients regarding the ATA guidelines and comment on individual
patient’s characteristics deviating from the expected phenotype.
1.1 Patients andmethods
Data collection was prospectively conducted in the GPOH-MET
97 study and the GPOH-MET registry. The GPOH-MET 97 study
was a prospective multicenter interdisciplinary nonrandomized trial
collecting data on children and adolescents with malignant endocrine
tumors (MET), including MTC and CCH. Since January 2013, the
GPOH-MET 97 study has continued as the GPOH-MET registry. Chil-
dren and adolescents aged 0 to 18 years were analyzed.
Patients were diagnosed according to the TNM classification sys-
tem by local pathology assessment. Noteworthy, the 8th edition of the
American JointCommitteeonCancer (AJCC)/TNMcancer staging sys-
tem was introduced on January 1, 2018. One important modification
was that the microscopic extrathyroidal tumor invasion is no longer
considered as a criterion for the classification as a T3 tumor.18 How-
ever, in our cohort, only one patient was diagnosed after this refer-
ence date and was not affected by this modification. Consistently, the
reported data were classified according to the previous edition of the
classification system.
TheGPOH-MET97 studyprotocol and the recommendations of the
GPOH-MET registry document were conducted according to the Dec-
laration ofHelsinki and approved by the ethical committees of theUni-
versity of Luebeck (97-125) andOtto von Guericke UniversityMagde-
burg (174/12), Germany.Written informed consentwas obtained from
either the patients themselves, if theywere aged 15 years or older, and
the child’s parents or legal guardians, respectively.
Due to missing data in some patients, the exact number of cases
used for the frequency analyses (including only those patients inwhom
data were available) varied and is given in the tables. Overall survival
(OS) and event-free survival (EFS) were calculated using the Kaplan-
Meiermethod; groupswere compared using the log-rank test. For esti-
mation of OS, death of any cause was used as an event, for EFS, non-
remission, persisting/increased calcitonin levels, development of new
metastases, second malignancies, and death of any cause were used.
Survivors were censored at the last date of last known follow-up. Cox
proportional hazards model was used to evaluate the impact of prog-
nostic factors on EFS in a univariate andmultivariatemanner including
the following factors potentially associated with outcome: indication
for thyroidectomy, pN, pM, postoperative calcitonin levels, and type of
MEN2 syndrome. All P values below 0.05 were considered significant.
Statistical analyses were performed by SPSS version 26. Data will be
made available upon reasonable request.
2 RESULTS
2.1 Childrenwithmedullary thyroid carcinoma
From 1997 to June 2019, a total of 57 children and adolescents with
MTC were registered within the GPOH-MET databases with a mean
follow-up of 5.8 years (SD ±4.8). Detailed patient characteristics are
given in Table 1. OS and EFS of children diagnosedwithMTCwere 87%
and 52%, respectively.
Preoperative calcitonin levels were above 100 ng/l in nine (20.0%)
of the patients (thereof pN1 = 5, pM1 = 1), 14 (30.4%) presented with
calcitonin levels above 1000 ng/l (pN1 = 13, pM1 = 9). Details of pre-
operative calcitonin levels, CEA levels, and radiological diagnostics are
given in Table 2.
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TABLE 1 Demographic and clinical characteristics of children and
adolescents withMTC (n= 57)
Children
withMTC MEN2A MEN2B
No 57a 27 27
Gender
Female 25 (43.9%) 12 (44.4%) 14 (51.9%)
Male 32 (56.1%) 15 (55.6%) 13 (48.1%)
Age at diagnosis
Mean (SD) 9.9 (5.0) 9.6 (4.7) 9.2 (5.3)
Median (range in
years)
10 (0-17) 9 (1-17) 10 (0-17)
Time of follow-up
Mean (SD) 5.8 (4.8) 5.4 (4.6) 5.3 (4.8)
Median (range in
years)
5 (0-19) 5 (0-17) 5 (0-19)
TNM classification
pT1 33 (57.9%) 21 (77.8%) 12 (44.4%)
pT2 4 (7.0%) 1 (3.7%) 1 (3.7%)
pT3 4 (7.0%) 1 (3.7%) 3 (11.1%)
pT4 11 (19.3%) 0 10 (37.0%)
Unknown 5 (8.8%) 4 (14.8%) 1 (3.7%)
pN0 28 (49.1%) 20 (74.1%) 8 (29.6%)
pN1 26 (45.6%) 4 (14.8%) 19 (70.4%)
Unknown 3 (5.3%) 3 (11.1%) 0
pM0 42 (73.7%) 24 (%) 16 (59.3%)
pM1 13 (22.8%)b 1 (3.7%) 11 (40.7%)
Unknown 2 (3.5%) 2 (7.4%) 0
Remission at last
follow-up
Complete remission 28 (49.1%) 20 (74.1%) 8 (29.6%)
Partial remission 2 (3.5%) 0 2 (7.4%)
Stable disease 4 (7.0%) 1 (3.7%) 3 (11.1%)
Progressive disease 10 (17.5%) 0 8 (29.6%)
Hypercalcitoninemia 4 (7.0%) 2 (7.4%) 1 (3.7%)
Death 6 (10.5%) 1 (3.7%) 5 (18.5%)
Unknown 3 (5.3%) 3 (11.1%) 0
Status at last follow-up
Alive 47 (82.5%) 23 (85.2%) 22 (81.5%)
Deceased 8 (14.1%) 1 (3.7%) 5 (18.5%)
Unknown 3 (5.3%) 3 (11.1%) 0
aSomatic RET mutation n = 1; no somatic and no germline RET mutation
n= 2.
bLung n= 13, liver n= 5, bone n= 2, cerebral n= 2.
n/a, not applicable; SD, standard deviation; TNM, tumor nodemetastasis.
In 25 (43.9%) patients, prophylactic TE was performed, and 21
(36.8%) patients underwent therapeutic TE. Details of surgical treat-
ment are given in Table 3.
Postoperative complications included unilateral recurrent
laryngeal nerve (RLN) paralysis in four (25%) patients with a
preoperatively functioning RLN. Due to extensive tumor invasion
including preoperative RLN paralysis, unilateral RLN resection was
performed in five patients and bilateral resection in two patients
(requiring tracheostomy).
Permanent hypoparathyroidism was reported in 12 (26.7%)
patients. Hypoparathyroidism occurred significantly more frequently
in patients undergoing therapeutic TE compared with prophylactic TE
(P= 0.016).
Postoperative calcitonin levels were not detectable in 12 (26.1%)
patients, normalized in 15 (32.6%), and remained elevated in 19
(41.3%) patients.
Only a minority of patients (n = 12; 21.1%)—all with advanced
local and/or metastatic disease—received additional therapy. Details
of therapeutic modalities are given in Table 3. Seven (12.3%) patients
underwent combinatorial treatment approaches.
At last follow-up, of 13 children and adolescents with metastatic
disease at diagnosis, five (38.5%) had subsequently died due to their
disease, one (7.7%) due to acute airway obstruction, and one (7.7%)
due to an accident (both patients were extensively metastasized).
Five patients did not achieve a complete remission (CR), subsequently
developednewmetastasesor relapsed, respectively.Of the13patients
with lymph nodemetastases at initial presentation, only three (23.1%)
achieved a complete or partial remission,whereas 9 (69.2%) developed
elevated calcitonin levels andmetastases, respectively.
With regard to calcitonin levels, only one (7.1%) patient with calci-
tonin levels above 1000 pg/mL achieved a CR, five (35.7%) had died at
last follow-up.
2.2 Childrenwith C-cell hyperplasia
In addition to patients with MTC, 17 children and adolescents with
CCHwere reported to the GPOH-MET registry. Themean age at diag-
nosis of CCH was 6.8 years (SD 3.9), and the mean follow-up was
1.6 years (SD 2.7).
Pathologic calcitonin levels (mean 13.3 pg/mL, SD 7.0) were
reported in 77.8% (n = 7) of the patients. CCH most frequently
occurredmultifocal (66.7%). Apart from prophylactic TE, no additional
treatmentwas given in these children.Neither paralysis of theRLNnor
hypoparathyroidism was reported as postoperative complications fol-
lowing prophylactic TE for CCH. Until last follow-up, no child devel-
oped disease progression/relapse or PHEO.
2.3 Children affected byMEN2 syndrome
MEN2 syndromewas reported in 70 (94.6%) children and adolescents;
of these, 42 (60.0%) were diagnosed withMEN2A and 28 (40.0%) with
MEN2B syndrome. MEN2A syndrome was inherited in 37 children
(unknown in n = 3) and MEN2B syndrome in three children (unknown
in n= 4).
The majority of children (n = 24, 66.7%) with MEN2A syndrome
carried the pathogenic RET codon 634 mutation in the cadherin-like
domain of exon 11 followed by pathogenic mutations in the tyrosine
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TABLE 2 Overview of diagnostics and preoperative, postoperative, and follow-up levels of biomarkers in children and adolescents withMTC
Children
withMTC MEN2A MEN2B
(n= 57)a (n= 27) (n= 27)
Diagnostics
Ultrasound of the neck
Normal 17 (29.8%) 12 (44.4%) 4 (14.8%)
Uncertain 4 (7.0%) 1 (3.7%) 17 (63.0%)
Pathologic 25 (43.9%) 6 (22.2%) 3 (11.1%)
Not done 11 (19.3%) 8 (29.6%) 3 (11.1%)
Magnetic resonance
imaging
No tumor detectable 6 (10.5%) 1 (3.7%) 6 (22.2%)
Tumor verified 19 (33.3%) 1 (3.7%) 14 (51.9%)
Not done 32 (56.1%) 25 (92.6%) 7 (25.9%)
PET imaging
Negative 1 (1.8%) 1 (3.7%) 0
Uncertain 1 (1.8%) 0 0
Positive 6 (10.5%) 0 6 (22.2%)
Not done 49 (86.0%) 26 (96.3%) 21 (77.8%)
Biochemical markers Preoperative Postoperative Preoperative Postoperative Preoperative Postoperative
Calcitonin (ng/l; normal< 5 female,< 8.4male)
Not detectable n/a 12 (21.1%) n/a 9 (33.3%) n/a 3 (11.1%)
Normal 5 (8.8%) 15 (26.3%) 5 (18.5%) 11 (40.7%) 0 4 (14.8%)
Pathologic 46 (80.7%) 19 (33.3%) 18 (66.7%) 1 (3.7%) 25 (92.6%) 15 (55.6%)











CEA (ng/ml; normal< 2.5)
Not detectable n/a 1 (1.8%) n/a 1 (3.7%) n/a 0
Normal 12 (21.1%) 8 (14.0%) 8 (29.6%) 3 (11.1%) 4 (14.8%) 5 (18.5%)
Pathologic 15 (26.3%) 8 (14.0%) 1 (3.7%) 1 (3.7%) 12 (44.4%) 6 (22.2%)









n/a, not applicable; PET, positron emission tomography.
aNoMEN syndrome in three patients.
kinase domain of exon 13 in codons 790 and 791 (n = 6; 16.7%). In six
children with MEN2A syndrome, RET variant data were not available.
Formutationpatterns andclinical characteristics of childrendiagnosed
withMEN2 syndrome, please refer to Figure 1 and Tables 1 to 3.
2.4 Revisiting the ATA criteria in children affected
byMEN2 syndrome
Referring to the ATA guideline in the current version (8th edition),
12 (19.4%) children were assigned to the “modest,” 24 (38.7%) to the
“high,” and 26 (41.9%) to the “highest” risk group. Details of age, pre-
operative calcitonin levels, and events in patients in each risk group are
given in Figure 1.
According to the ATA guideline, in the modest-risk group, TE is rec-
ommended above five years of age if basal calcitonin levels are within
normal limits. Noteworthy, in this group, one child (carrying a muta-
tion in codon 630) was diagnosed with MTC as early as one year of
age. In only two (40.0%) of five children who presented with MTC due
to pathogenic mutations in codons 611, 630, and 790, calcitonin lev-
els were elevated according to age and gender (missing information in
one patient). This highlights that calcitonin levels in pediatric RET car-
riers may be an insufficient biomarker. In line with this finding, in two
adolescents affected by the pathogenic high-riskC634mutation, calci-
tonin levels at diagnosis ofMTC (at 12 and 14 years of age)werewithin
the normal range.
The ATA recommendations also take into account aggressiveness
of the disease as reflected by the potential to develop metastatic
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TABLE 3 Overview on treatment in children and adolescents withMTC
Children
withMTC MEN2A MEN2B
(n= 57)a (n= 27) (n= 27)
Treatment
Type of first surgery
Prophylactic TE 25 (43.9%)b 21 (77.8%) 4 (14.8%)
Therapeutic TE 21 (36.8%) 2 (7.4%) 18 (66.7%)
Total TE 18 2 15
Subtotal thyroidectomy 2 0 2
Hemithyroidectomy 1 0 1
Lymphadenectomy only 3 (5.3%) 0 2 (7.4%)
Biopsy only 2 (3.5%) 1 (3.7%) (liver) 1 (3.7%) (lung)
Unknown 6 (10.5%) 3 (11.1%) 2 (7.4%)
Second surgery 7 (12.3%) 0 7 (25.9%)
Radiotherapy
No 53 (93.0%) 26 (96.3%) 24 (88.9%)
Yes 3 (5.3%) 0 3 (11.1%)
Unknown 1 (1.8%) 1 (3.7%) 0
Chemotherapyc
No 50 (87.7%) 25 (92.6%) 22 (81.5%)
Yes 6 (10.5%)d 1 (3.7%) 5 (18.5%)
Unknown 1 (1.8%) 1 (3.7%) 0
Octreotide therapy
No 52 (91.2%) 23 (85.2%) 26 (96.3%)
Yes 1 (1.8%) 1 (3.7%) 0
Unknown 4 (7.0%) 3 (11.1%) 1 (3.7%)
Radioiodine therapy
No 52 (91.2%) 23 (85.2%) 26 (96.3%)
Yes 2 (3.5%) 1 (3.7%) 1 (3.7%)
Unknown 3 (5.3%) 3 (11.1%) 0
Compassionate use
No 45 (78.9%) 23 (85.2%) 19 (70.4%)
Yes 9 (15.8%)e 1 (3.7%) 8 (29.6%)
Unknown 3 (5.3%) 3 (11.1%) 0
CCH, C-cell hyperplasia; LND, lymph node dissection,MTC, medullary thyroid carcinoma; n/a, not applicable; TE, thyroidectomy.
aNoMEN syndrome in three patients.
bDue to increased calcitonin levels n= 19; on families wish n= 6.
cConsisting of either vincristine, carboplatin, and etoposide or vindesine, ifosfamide, dacarbazine, and adriamycin.
dResulting in stable disease and progressive disease in three patients each.
eInterferon alpha n= 2, imatinib n= 1, vandetanib n= 4, sorafenib n= 1, and sunitinib n= 1.
disease. Advanced local (pT3/4) and metastatic disease (pM1) were
present only in children affected by mutations in codons 634 and
918. In line with this, children carrying theM918Tmutation were fre-
quently affected by advanced local disease (n=13; 50.0%), lymphnode
(n=18; 69.2%), and distantmetastases (n=10; 38.5%). However, look-
ing closely at the modest-risk group, in which MTC is assumed to be
less aggressive, it is noteworthy that one child (aged 11 years; codon
790) presentedwith lymphnodemetastases (pN1) at diagnosis ofMTC
(missing information on calcitonin levels) and one child (codon 611)
developed lymph node metastases three years after the diagnosis of
MTC.
Except for one child carrying a codon 634 mutation (in whom
distant metastases were already present at initial diagnosis of
MTC), children dying due to MTC were only affected by the RET
codon M918T mutation. Of the 17 children who subsequently devel-
oped any disease-associated event other than death, 13 children
were carriers of the M918T mutation and one child of a codon
634mutation.
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F IGURE 1 RETmutations, ATA risk stratification, and clinical
presentation in 59 patients affected byMTC and CCH. ATA, American
Thyroid Association; CCH, C-Cell hyperplasia; CLD, cadherin-like
domain; CRD, cysteine-rich domain; green, modest risk; JM,
juxtamembrane domain; pts, patients; red, highest risk; TK, tyrosine
kinase domain; TM, transmembrane domain; yellow, high risk
The ATA guideline takes the lifetime risk to develop MTC, PHEO,
and PHTP into account. In line with this, thus far, two children carrying
the RET codonM918Tmutation developed PHEO, whereas in children
carrying “H” and “MOD”mutations, no other malignancy was reported
so far.
2.5 Prognostic factors for outcome
Differences in OS and EFS were observed between indication for
thyroidectomy (prophylactic vs therapeutic), lymph node, and distant
metastases status at diagnosis, and postoperative calcitonin levels
(Figure 2A-D). Patients with MEN2B syndrome did worse when com-
pared with those with MEN2A syndrome (10-year EFS 38% vs 78%,
P< 0.001).
In multivariate analysis of EFS (including indication for thyroidec-
tomy, pN status, pM status, postoperative calcitonin status, and type of
MEN syndrome), the presence of lymph nodemetastases (HR= 10.92,
95% confidence interval [CI], 1.89-62.99, P = 0.008) and postopera-
tive elevated calcitonin (HR = 7.34, 95% CI, 1.18-45.84; P = 0.033)
were identified as significant adverse prognostic factors. The type of
MEN2 syndrome had no significant influence on outcome (HR = 3.10,
P= 0.401).
3 DISCUSSION
This is the first report on children andadolescents diagnosedwithMTC
and CCH reported to the German GPOH-MET registry. In line with
previous reports on patients with MTC,1,2,4,6,8,9,11,19–22 children and
adolescents presenting with localized disease at diagnosis of MTC had
an excellent outcome, whereas children with metastatic disease did
worse.
The standard treatment for MTC is the surgical removal of all
thyroid and tumor tissue, respectively.23,24 On the other hand, sur-
gical cure is virtually impossible, when 10 or more lymph nodes
are involved or serum calcitonin levels exceed 1000 ng/l.25,26 In our
study, 45% of patients presented with lymph node metastases and
23% with distant metastases at diagnosis. In line with known out-
come predictors in MTC,27,28 lymph node metastases and elevated
calcitonin postoperatively (as a sign of persistent disease) were inde-
pendently associated with poorer outcome on EFS in multivariable
analyses.
MTC does not respond to radiotherapy and standard cyto-
toxic chemotherapy.29,30 Therapeutic options other than surgery
are scarce for patients with advanced disease. The multikinase
inhibitors vandetanib and cabozantinib (including the inhibition of
RET) have been approved for the treatment of inoperable (progres-
sive) MTC.31,32 In phase I/II trials of vandetanib in children, par-
tial response rates of 47% to 58% have been reported.33,34 Vande-
tanib was administered in a compassionate need intention to four
of our patients with progressive disease. One patient subsequently
died due to MTC, and the remaining patients are in progressive
disease.
Pediatric (hereditary) MTC is deemed to be a paramount exam-
ple of a striking genotype-phenotype correlation, including an age-
relatedprogression toMTCdepending on the respectiveRET sequence
variant. Corresponding to the ATA risk estimation, children car-
rying variants in codon 634 and particularly in codon 918 pre-
sented with more advanced and aggressive disease and had a poorer
outcome than children carrying modest-risk variants. Of note, the
type of MEN syndrome had no impact on EFS in multivariate
analysis.
Our data clearly indicate that particular attention is required for
carriers of modest-risk variants. The phenotypemay bemore variable,
and recommendations are primarily based on few data confronting
treating physicianswith greater inaccuracy. This is impressively under-
lined by five children from our cohort carrying modest-risk variants,
in whom MTC was diagnosed as early as one year of age, was accom-
panied by lymph node metastases, or was associated with calcitonin
levels within the normal range.
Typically, MTC cells secrete calcitonin. For that reason, serum cal-
citonin is generally used as a biomarker for detection, staging, post-
operative management, and prognostication in MTC patients.35 How-
ever, in some cases, MTC cells do not secrete calcitonin and, thus,
cannot be detected and followed by monitoring of this biomarker.36
This is indeed crucial when monitoring carriers of pathogenic
modest-risk RET mutations, in whom the ATA guidelines thus far
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F IGURE 2 Probability of EFS depending on the indication for thyroidectomy (A), the presence of lymph nodemetastases (B) and distant
metastases (C) at diagnosis, and postoperative calcitonin levels (D)
recommend prophylactic TE based on calcitonin levels. According to
our calcitonin data, this recommendation may be misleading at least
in modest-risk mutation carriers. We suggest it may require revi-
sion based on larger patient numbers and include prophylactic TE in
childhood.
Another feature of MEN2 syndrome is that predictive genetic
testing is recommended as early as six months of age in families
carrying the M918T variant.37,38 By identifying carriers and per-
forming prophylactic TE before the development of MTC, incidence
and mortality of MTC in families affected by MEN2 syndrome have
significantly been reduced.39 In line with previous reports,16,17 in
85.7% of children and adolescents affected by MEN2B syndrome,
the aggressive RET M918T mutation occurred de novo, however. In
these patients, prophylactic or early TE could not be performed;
instead, MTC was diagnosed at an advanced and even metastatic
stage. For these patients, novel therapeutic approaches are urgently
needed.
4 CONCLUSION
In children and adolescents enrolled in theGPOH-MET registry, lymph
node status and postoperative elevated calcitonin were identified as
significant prognostic factors for EFS. To avoid the occurrence of
advanced MTC and to improve survival, the identification of children
carrying de novo RET M918Tmutations by means of the characteristic
phenotype is crucial.
Notably, modest-risk mutation carriers presented with a variable
phenotype including false-negative calcitonin levels and, thus, need
particular attention.
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